10 results on '"Liu, Xiuli"'
Search Results
2. Development of a Scoring System to Differentiate Amiodarone-Induced Liver Injury From Alcoholic Steatohepatitis.
- Author
-
González IA, Fuller LD, Zhang X, Papke DJ, Zhao L, Zhang D, Liao X, Liu X, Fiel MI, and Zhang X
- Subjects
- Humans, Liver pathology, Amiodarone adverse effects, Chemical and Drug Induced Liver Injury, Chronic pathology, Fatty Liver chemically induced, Fatty Liver diagnosis, Fatty Liver pathology, Fatty Liver, Alcoholic diagnosis, Fatty Liver, Alcoholic pathology
- Abstract
Objectives: Amiodarone-induced liver injury (AILI) is histopathologically similar to alcoholic steatohepatitis (ASH). We sought to elucidate their histologic differences and develop a scoring system to differentiate these two entities., Methods: A cohort of 17 AILI and 17 ASH cases was included in the initial study. Cases from three different institutions were included for further validation., Results: Macrovesicular steatosis was usually below 10% of the liver parenchyma in AILI. Hepatocyte ballooning degeneration was more common in ASH than in AILI. "Balloon-like" hepatocyte was more common in AILI than in ASH. Lobular neutrophilic inflammation, satellitosis, and cholestasis were more common in ASH. Mallory-Denk bodies and pericellular fibrosis in AILI were mainly located in zone 1 compared with a panacinar or zone 3 distribution in ASH. A scoring system was developed in which points were assigned to different histologic features; a total sum of less than 5 suggests AILI, more than 5 is ASH, and 5 is equivocal. This scoring system was then evaluated on a test cohort comprising 14 AILI cases, in which 13 cases were correctly assigned with a score less than 5. The sensitivity, specificity, and accuracy for diagnosing AILI in the test cohort were 92.9%, 91.7%, and 92.3%, respectively., Conclusions: This scoring system can aid pathologists to differentiate AILI from ASH., (© American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
3. Liver-on-a-Chip Models of Fatty Liver Disease.
- Author
-
Hassan S, Sebastian S, Maharjan S, Lesha A, Carpenter AM, Liu X, Xie X, Livermore C, Zhang YS, and Zarrinpar A
- Subjects
- Humans, Models, Structural, Fatty Liver, Lab-On-A-Chip Devices
- Published
- 2020
- Full Text
- View/download PDF
4. Deficiency of liver Comparative Gene Identification-58 causes steatohepatitis and fibrosis in mice.
- Author
-
Guo F, Ma Y, Kadegowda AKG, Betters JL, Xie P, Liu G, Liu X, Miao H, Ou J, Su X, Zheng Z, Xue B, Shi H, and Yu L
- Subjects
- 1-Acylglycerol-3-Phosphate O-Acyltransferase deficiency, 1-Acylglycerol-3-Phosphate O-Acyltransferase genetics, Animals, Fatty Liver pathology, Female, Liver pathology, Liver Cirrhosis pathology, Mice, Mice, Inbred C57BL, Mice, Knockout, 1-Acylglycerol-3-Phosphate O-Acyltransferase metabolism, Fatty Liver metabolism, Liver metabolism, Liver Cirrhosis metabolism
- Abstract
Triglyceride (TG) accumulation in hepatocytes (hepatic steatosis) preludes the development of advanced nonalcoholic fatty liver diseases (NAFLDs) such as steatohepatitis, fibrosis, and cirrhosis. Mutations in human Comparative Gene Identification-58 (CGI-58) cause cytosolic TG-rich lipid droplets to accumulate in almost all cell types including hepatocytes. However, it is unclear if CGI-58 mutation causes hepatic steatosis locally or via altering lipid metabolism in other tissues. To directly address this question, we created liver-specific CGI-58 knockout (LivKO) mice. LivKO mice on standard chow diet displayed microvesicular and macrovesicular panlobular steatosis, and progressed to advanced NAFLD stages over time, including lobular inflammation and centrilobular fibrosis. Compared with CGI-58 floxed control littermates, LivKO mice showed 8-fold and 52-fold increases in hepatic TG content, which was associated with 40% and 58% decreases in hepatic TG hydrolase activity at 16 and 42 weeks, respectively. Hepatic cholesterol also increased significantly in LivKO mice. At 42 weeks, LivKO mice showed increased hepatic oxidative stress, plasma aminotransferases, and hepatic mRNAs for genes involved in fibrosis and inflammation, such as α-smooth muscle actin, collagen type 1 α1, tumor necrosis factor α, and interleukin-1β. In conclusion, CGI-58 deficiency in the liver directly causes not only hepatic steatosis but also steatohepatitis and fibrosis.
- Published
- 2013
- Full Text
- View/download PDF
5. Macrophage migration inhibitory factor contributes to ethanol-induced liver injury by mediating cell injury, steatohepatitis, and steatosis.
- Author
-
Barnes MA, McMullen MR, Roychowdhury S, Pisano SG, Liu X, Stavitsky AB, Bucala R, and Nagy LE
- Subjects
- Alanine Transaminase metabolism, Animals, Aspartate Aminotransferases metabolism, Chemokines metabolism, Disease Models, Animal, Female, Hepatocytes drug effects, Hepatocytes metabolism, Hepatocytes pathology, Intramolecular Oxidoreductases genetics, Lipopolysaccharides pharmacology, Macrophage Migration-Inhibitory Factors genetics, Mice, Mice, Inbred C57BL, Mice, Knockout, RNA, Messenger metabolism, Triglycerides metabolism, Tumor Necrosis Factor-alpha metabolism, Chemical and Drug Induced Liver Injury metabolism, Ethanol adverse effects, Fatty Liver metabolism, Fatty Liver pathology, Intramolecular Oxidoreductases metabolism, Liver metabolism, Liver pathology, Macrophage Migration-Inhibitory Factors metabolism
- Abstract
Unlabelled: Macrophage migration inhibitory factor (MIF), a multipotent protein that exhibits both cytokine and chemotactic properties, is expressed by many cell types, including hepatocytes and nonparenchymal cells. We hypothesized that MIF is a key contributor to liver injury after ethanol exposure. Female C57BL/6 or MIF-/- mice were fed an ethanol-containing liquid diet or pair-fed control diet for 4 (11% total kcal;early response) or 25 (32% kcal; chronic response) days. Expression of MIF messenger RNA (mRNA) was induced at both 4 days and 25 days of ethanol feeding. After chronic ethanol, hepatic triglycerides and plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were increased in wildtype, but not MIF-/-, mice. In order to understand the role of MIF in chronic ethanol-induced liver injury, we investigated the early response of wildtype and MIF-/- to ethanol. Ethanol feeding for 4 days increased apoptosis of hepatic macrophages and activated complement in both wildtype and MIF-/- mice. However, tumor necrosis factor alpha (TNF-α) expression was increased only in wildtype mice. This attenuation of TNF-α expression was associated with fewer F4/80+ macrophages in liver of MIF-/- mice. After 25 days of ethanol feeding, chemokine expression was increased in wildtype mice, but not MIF-/- mice. Again, this protection was associated with decreased F4/80+ cells in MIF-/- mice after ethanol feeding. Chronic ethanol feeding also sensitized wildtype, but not MIF-/-, mice to lipopolysaccharide, increasing chemokine expression and monocyte recruitment into the liver., Conclusion: Taken together, these data indicate that MIF is an important mediator in the regulation of chemokine production and immune cell infiltration in the liver during ethanol feeding and promotes ethanol-induced steatosis and hepatocyte damage., (Copyright © 2012 American Association for the Study of Liver Diseases.)
- Published
- 2013
- Full Text
- View/download PDF
6. CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance.
- Author
-
Brown JM, Betters JL, Lord C, Ma Y, Han X, Yang K, Alger HM, Melchior J, Sawyer J, Shah R, Wilson MD, Liu X, Graham MJ, Lee R, Crooke R, Shulman GI, Xue B, Shi H, and Yu L
- Subjects
- Adipocytes, White metabolism, Animals, Dietary Fats adverse effects, Fatty Liver metabolism, Gene Expression Regulation genetics, Glucose Intolerance etiology, Glucose Intolerance genetics, Insulin Resistance genetics, Liver metabolism, Male, Mice, Mice, Inbred C57BL, Obesity etiology, Obesity genetics, Oligonucleotides, Antisense genetics, Phospholipids metabolism, Triglycerides metabolism, 1-Acylglycerol-3-Phosphate O-Acyltransferase deficiency, 1-Acylglycerol-3-Phosphate O-Acyltransferase genetics, Diet adverse effects, Fatty Liver genetics, Gene Knockdown Techniques, Glucose Intolerance prevention & control, Obesity prevention & control
- Abstract
Mutations of Comparative Gene Identification-58 (CGI-58) in humans cause triglyceride (TG) accumulation in multiple tissues. Mice genetically lacking CGI-58 die shortly after birth due to a skin barrier defect. To study the role of CGI-58 in integrated lipid and energy metabolism, we utilized antisense oligonucleotides (ASOs) to inhibit CGI-58 expression in adult mice. Treatment with two distinct CGI-58-targeting ASOs resulted in ∼80-95% knockdown of CGI-58 protein expression in both liver and white adipose tissue. In chow-fed mice, ASO-mediated depletion of CGI-58 did not alter weight gain, plasma TG, or plasma glucose, yet raised hepatic TG levels ∼4-fold. When challenged with a high-fat diet (HFD), CGI-58 ASO-treated mice were protected against diet-induced obesity, but their hepatic contents of TG, diacylglycerols, and ceramides were all elevated, and intriguingly, their hepatic phosphatidylglycerol content was increased by 10-fold. These hepatic lipid alterations were associated with significant decreases in hepatic TG hydrolase activity, hepatic lipoprotein-TG secretion, and plasma concentrations of ketones, nonesterified fatty acids, and insulin. Additionally, HFD-fed CGI-58 ASO-treated mice were more glucose tolerant and insulin sensitive. Collectively, this work demonstrates that CGI-58 plays a critical role in limiting hepatic steatosis and maintaining hepatic glycerophospholipid homeostasis and has unmasked an unexpected role for CGI-58 in promoting HFD-induced obesity and insulin resistance.
- Published
- 2010
- Full Text
- View/download PDF
7. Resolution of nonalcoholic steatohepatits after gastric bypass surgery.
- Author
-
Liu X, Lazenby AJ, Clements RH, Jhala N, and Abrams GA
- Subjects
- Adult, Body Mass Index, Fatty Liver complications, Female, Follow-Up Studies, Hepatitis complications, Humans, Laparoscopy, Male, Middle Aged, Obesity, Morbid pathology, Remission Induction, Retrospective Studies, Treatment Outcome, Fatty Liver pathology, Gastric Bypass, Hepatitis pathology, Obesity, Morbid complications, Obesity, Morbid surgery, Weight Loss
- Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) has been increasingly recognized as a common chronic liver condition. Previous studies have been variable regarding the histological outcomes after rapid weight loss. The aim of this study was to characterize the histopathologic changes in NASH following laparoscopic Roux-en-Y Gastric Bypass surgery (LRYGBP)., Methods: We retrospectively analyzed paired needle liver biopsies taken during and following LRYGBP in 39 patients according to the recent NIH-based NAFLD criteria., Results: The cohort included 33 females and 6 males (range 24-57 years). 23 patients (58.9%) had steatohepatitis, 12 with fatty liver (30.7%), and 4 were normal (10.2%). Follow-up needle liver biopsies were performed at a mean interval of 18 months (range 6-41 months). No significant differences in length or number of portal tracts between the paired biopsies were noted. The mean decrease in weight and BMI was 50.2 kg and 18.2 kg/m2, respectively. The initial prevalence of hepatic pathology: steatosis (89.7%), hepatocellular ballooning (58.9%), and centrilobular/perisinusoidal fibrosis (50%) improved significantly after LRYGBP: steatosis (2.9%), ballooning (0%), and centrilobular fibrosis (25%). Mitigation in the lobular inflammation score (2.23+/-0.63 vs 1.95+/-0.56, P=0.01) and stage of fibrosis (1.14+/-1.05 to 0.72+/-0.97, P=0.002) were also noted. However, no improvements were detected in portal tract inflammation and fibrosis., Conclusions: Over a mean period of 18 months, histological improvements and resolution of NASH occurs after LRYGBP. Long-term studies are warranted to assess for potential changes in the portal regions or relapse of NASH that could result with weight regain or malnutrition.
- Published
- 2007
- Full Text
- View/download PDF
8. Targeted and untargeted metabolomics provide insight into the consequences of glycine‐N‐methyltransferase deficiency including the novel finding of defective immune function.
- Author
-
Eudy, Brandon J., McDermott, Caitlin E., Liu, Xiuli, and Silva, Robin P.
- Subjects
METABOLOMICS ,NICOTINAMIDE ,DNA methyltransferases ,LOW-fat diet ,FATTY liver ,HEPATIC fibrosis ,SMALL molecules ,LIVER histology ,ENZYME metabolism - Abstract
Fatty liver disease is increasing along with the prevalence of obesity and type‐2 diabetes. Hepatic fibrosis is a major health complication for which there are no efficacious treatment options available. A better understanding of the fundamental mechanisms that contribute to the accumulation of fibrosis is needed. Glycine‐N‐methyltransferase (GNMT) is a critical enzyme in one‐carbon metabolism that serves to regulate methylation and remethylation reactions. GNMT knockout (GNMT‐/‐) mice display spontaneous hepatic fibrosis and later develop hepatocellular carcinoma. Previous literature supports the idea that hypermethylation as a consequence of GNMT deletion contributes to the hepatic phenotype observed. However, limited metabolomic information is available and the underlying mechanisms that contribute to hepatic fibrogenesis in GNMT‐/‐ mice are still incomplete. Therefore, our goals were to use dietary intervention to determine whether increased lipid load exacerbates steatosis and hepatic fibrosis in this model and to employ both targeted and untargeted metabolomics to further understand the metabolic consequences of GNMT deletion. We find that GNMT mice fed high‐fat diet do not accumulate more lipid or fibrosis in the liver and are in fact resistant to weight gain. Metabolomics analysis confirmed that pan‐hypermethylation occurs in GNMT mice resulting in a depletion of nicotinamide intermediate metabolites. Further, there is a disruption in tryptophan catabolism that prevents adequate immune cell activation in the liver. The chronic cellular damage cannot be appropriately cleared due to a lack of immune checkpoint activation. This mouse model is an excellent example of how a disruption in small molecule metabolism can significantly impact immune function. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis.
- Author
-
Kasumov, Takhar, Li, Ling, Li, Min, Gulshan, Kailash, Kirwan, John P., Liu, Xiuli, Previs, Stephen, Willard, Belinda, Smith, Jonathan D., and McCullough, Arthur
- Subjects
CERAMIDES ,FATTY liver ,ATHEROSCLEROSIS ,CARDIOVASCULAR diseases ,COMORBIDITY ,SPHINGOMYELIN - Abstract
Cardiovascular disease (CVD) is a serious comorbidity in nonalcoholic fatty liver disease (NAFLD). Since plasma ceramides are increased in NAFLD and sphingomyelin, a ceramide metabolite, is an independent risk factor for CVD, the role of ceramides in dyslipidemia was assessed using LDLR-/- mice, a diet-induced model of NAFLD and atherosclerosis. Mice were fed a standard or Western diet (WD), with or without myriocin, an inhibitor of ceramide synthesis. Hepatic and plasma ceramides were profiled and lipid and lipoprotein kinetics were quantified. Hepatic and intestinal expression of genes and proteins involved in insulin, lipid and lipoprotein metabolism were also determined. WD caused hepatic oxidative stress, inflammation, apoptosis, increased hepatic long-chain ceramides associated with apoptosis (C16 and C18) and decreased very-long-chain ceramide C24 involved in insulin signaling. The plasma ratio of ApoB/ApoA1 (proteins of VLDL/LDL and HDL) was increased 2-fold due to increased ApoB production. Myriocin reduced hepatic and plasma ceramides and sphingomyelin, and decreased atherosclerosis, hepatic steatosis, fibrosis, and apoptosis without any effect on oxidative stress. These changes were associated with decreased lipogenesis, ApoB production and increased HDL turnover. Thus, modulation of ceramide synthesis may lead to the development of novel strategies for the treatment of both NAFLD and its associated atherosclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
10. Inhibition of Apoptosis Protects Mice from Ethanol-Mediated Acceleration of Early Markers of CCl4-Induced Fibrosis but not Steatosis or Inflammation.
- Author
-
Roychowdhury, Sanjoy, Chiang, Dian J., Mandal, Palash, McMullen, Megan R., Liu, Xiuli, Cohen, Jessica I., Pollard, John, Feldstein, Ariel E., and Nagy, Laura E.
- Subjects
ALCOHOLIC liver diseases ,ANIMAL experimentation ,APOPTOSIS ,BIOLOGICAL assay ,BIOLOGICAL models ,ETHANOL ,EXTRACELLULAR space ,FATTY liver ,HYDROCARBONS ,IMMUNOHISTOCHEMISTRY ,INFLAMMATION ,RESEARCH methodology ,MICE ,MUSCLE proteins ,POLYMERASE chain reaction ,PROTEIN kinases ,PROTEINS ,PROTEOLYTIC enzymes ,RESEARCH funding ,STATISTICAL sampling ,TISSUE culture ,TRANSFERASES ,WESTERN immunoblotting ,FIBROSIS ,DATA analysis software ,STATISTICAL models ,DESCRIPTIVE statistics ,CHEMICAL inhibitors - Abstract
Background: Correlative evidence indicates that apoptosis is associated with the progression of alcoholic liver disease. If apoptosis contributes to ethanol ( EtOH)-induced steatohepatitis and/or fibrosis, then mice deficient in Bid, a key pro-apoptotic Bcl-2 family member, or mice treated with a pan-caspase inhibitor ( VX166) should be resistant to EtOH-induced liver injury. Methods: This hypothesis was tested in mice using a model of chronic, heavy EtOH-induced liver injury, as well as in a model in which moderate EtOH feeding accelerated the appearance of early markers of hepatic fibrosis in response to acute carbon tetrachloride (CCl
4 ) exposure. Results: Chronic EtOH feeding to mice increased TUNEL- and cytokeratin-18-positive cells in the liver, as well as the expression of receptor-interacting protein kinase 3 ( RIP3), a marker of necroptosis. In this model, Bid−/− mice or wild-type mice treated with VX166 were protected from EtOH-induced apoptosis, but not EtOH-induced RIP3 expression. Bid deficiency or inhibition of caspase activity did not protect mice from EtOH-induced increases in plasma alanine and aspartate amino transferase activity, steatosis, or mRNA expression of some inflammatory cytokines. Moderate EtOH feeding to mice enhanced the response of mice to acute CCl4 exposure, resulting in increased expression of α-smooth muscle actin and accumulation of extracellular matrix protein. VX166-treatment attenuated EtOH-mediated acceleration of these early indicators of CCl4 -induced hepatic fibrosis, decreasing the expression of α-smooth muscle actin, and the accumulation of extracellular matrix protein. Conclusions: EtOH-induced apoptosis of hepatocytes was mediated by Bid. Apoptosis played a critical role in the accelerating the appearance of early markers of CCl4 -induced fibrosis by moderate EtOH but did not contribute to EtOH-induced hepatocyte injury, steatosis, or expression of mRNA for some inflammatory cytokines. [ABSTRACT FROM AUTHOR]- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.